Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series

BACKGROUND: Neovascular age-related macular degeneration often requires chronic therapy with anti-VEGF agents, and patients with recurrent disease are challenging to manage. METHODS: This retrospective case series evaluates patients who were switched from bevacizumab or ranibizumab to aflibercept an...

Descripción completa

Detalles Bibliográficos
Autores principales: Slean, Geraldine R., Hemarat, Kornwipa, Khurana, Rahul N., Stewart, Jay M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088459/
https://www.ncbi.nlm.nih.gov/pubmed/27847620
http://dx.doi.org/10.1186/s40942-016-0028-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088459/
https://www.ncbi.nlm.nih.gov/pubmed/27847620
http://dx.doi.org/10.1186/s40942-016-0028-9

Ejemplares similares